Poseida Therapeutics

Poseida Therapeutics

Poseida Therapeutics develops targeted cell therapy.

Poseida Therapeutics is a privately held, biopharmaceutical company based in San Diego California. It leverages proprietary non-viral, gene engineering technologies to create therapeutics for illnesses with high unmet medical needs. The company is developing a wholly-owned pipeline of autologous and allogenic CAR-T product candidates, initially focused on the treatment of hematological malignancies and other solid tumors.

Poseida's leading product candidate is P-BCMA-101, an autologous CAR-T product that targets B cell maturation antigen, or BCMA, which is expressed on multiple myeloma cells. In December 2018, the company announced positive results from its first cohort of ongoing Phase 1 clinical trial. Poseida's second autologous product is P-PSMA-101, targeting cells that express prostate-specific membrane antigen, which is expressed on most prostate cancer cells. The product is being developed to treat patients with castrate-resistance prostate cancer, or CRPC, a solid tumor indication, with Phase 1 clinical trials planned in the second half of 2019.

Under the allogenic category, Poseida has P-BCMA-ALL01 and P-MUC1C-101. Derived from healthy donors, P-BCMA-ALL01 is designed to have the same inherent properties and functions of P-BCMA-101, but with the benefits of scale and administration efficiency that come from an allogenic product. The company plans to file an IND and begin Phase 1 clinical trials by late 2019 or early 2020. As for P-MUC1C-101, the product is in late-stage pre-clinical development for multiple solid tumor indications with plans for Phase 1 clinical trials in 2020.

In January 2019, Poseida Therapeutics filed documents for an IPO of $115 million.

Timeline

May 20, 2020

Poseida Therapeutics announces dosing of first patient in phase 1 clinical trial of P-PSMA-101 autologous CAR-T for metastatic castration-resistant prostate cancer.

April 2018

Poseida Therapeutics raises a $30,500,000 series B round from Tavistock Group, Longitude Capital, Vivo Capital and Malin Corporation.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Debra Gessner

VP, Regulatory Affairs

Devon J. Shedlock

VP, Preclinical Development

Eric Ostertag

CEO

Glenn Dourado

VP, Business Development

Jeff Knight

VP, Clinical Development Operations and Project Management

Jennifer Collins

VP, Quality Operations

Johanna Mylet

VP, Finance

Marcy Graham

VP, Corporate Affairs

Mark J. Gergen

Chief Business Officer and Chief Financial Officer

Martin Giedlin

VP, Technical Operations

Matthew A. Spear

Chief Medical Officer

Paiman Peter Ghoroghchian

Chief Technical Officer

Further reading

Title
Author
Link
Type
Date

Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting

Poseida Therapeutics, Inc.

Web

Xconomy: Poseida Therapeutics Prepares for IPO to Advance CAR-T Treatments

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Ben Adams
June 22, 2020
FierceBiotech
After ditching an attempted IPO earlier this year in favor of another funding round, CAR-T biotech Poseida Therapeutics is happy to go again.
BioSpace
May 20, 2020
BioSpace
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to utilizing proprietary non-viral gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, today announced the first patient has been dosed in its Phase 1 clinical trial evaluating P-PSMA-101, its au

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.